Methods for the treatment of HER2 amplified cancer
Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
1. A method for treating HER2 amplified cancer in an individual in need thereof, wherein the cancer is selected from the group consisting of endometrial, cervical, urothelial, ovarian, gastric, gastroesophageal junction (GEJ), head and neck, biliary tract, and prostate cancers, and the method comprises administering to the individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
Ibrutinib,
or a pharmaceutically acceptable solvate or pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the composition comprises ibrutinib.
3. The method of claim 1 , wherein the HER2-amplified cancer is metastatic.
4. The method of claim 1 , wherein the HER2-amplified cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0.
5. The method of claim 1 , wherein the HER2-amplified cancer is refractory to treatment.
6. The method of claim 1 , further comprising co-administering an additional therapeutic agent.
7. The method of claim 6 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent.
8. The method of claim 7 , wherein the anti-HER2 therapeutic agent is selected from the group consisting of: trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111.
9. The method of claim 7 , wherein the pan-ErbB inhibitor is selected from the group consisting of: afatinib, neratinib, and dacomitinib.
10. The method of claim 7 , wherein the anti-VEGF therapeutic agent is selected from the group consisting of: bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib.
11. The method of claim 6 , wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; ASLAN001; vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and 5-FU.